Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dalacin-T (brand name: Dalacin T) is a topical antibiotic formulation containing clindamycin phosphate (equivalent to 10 mg clindamycin per mL) used for the treatment of acne vulgaris, particularly forms in which comedones, papules, and pustules predominate. Clindamycin phosphate is a lincosamide antibiotic that is hydrolyzed *in vivo* to active clindamycin. It works by binding to the 50S ribosomal subunit of susceptible bacteria, such as *Cutibacterium acnes* (formerly *Propionibacterium acnes*), thereby inhibiting bacterial protein synthesis and preventing replication. Originally developed by Upjohn (now part of Pfizer), Dalacin-T is formulated as a topical lotion (aqueous emulsion) or topical solution and is typically applied to the affected skin twice daily.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin phosphate.